Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - NeuroBo Pharmaceuticals, Inc. | ex-99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 28, 2017 (June 28, 2017)
GEMPHIRE THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
Delaware |
|
001-37809 |
|
47-2389984 |
|
(State or other jurisdiction of incorporation) |
|
(Commission File No.) |
|
(IRS Employer Identification No.)
|
17199 N. Laurel Park Drive, Suite 401
Livonia, Michigan 48152
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (734) 245-1700
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
◻ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
◻ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
◻ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
◻ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 8.01 Other Events.
On June 28, 2017, Gemphire Therapeutics Inc. issued a press release announcing top-line data on the LDL-C primary endpoint from its COBALT-1 Phase 2b clinical trial of gemcabene in homozygous familial hypercholesterolemia (HoFH) patients.
A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Information contained on or accessible through any website reference in the press release is not part of, or incorporated by reference in, this Current Report on Form 8-K, and the inclusion of such website addresses in this Current Report on Form 8-K by incorporation by reference of the press release is as inactive textual references only.
|
Item 9.01 |
Financial Statements and Exhibits. |
|
(d) |
Exhibits. |
|
|
|
|
|
|
Exhibit |
|
Description |
|
|
|
|
|
99.1 |
|
Press Release dated June 28, 2017. |
|
|
|
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
GEMPHIRE THERAPEUTICS INC. |
||
|
Dated: June 28, 2017 |
|
|
|
|
|
|
|
|
|
|
|
By: |
|
/s/ Jeffrey S. Mathiesen |
|
|
|
|
|
|
|
Jeffrey S. Mathiesen |
|
|
|
|
|
|
|
Chief Financial Officer |
EXHIBIT INDEX
|
|
|
|
|
|
|
|
|
Exhibit |
|
Description |
|
|
|
|
|
99.1 |
|
Press Release dated June 28, 2017. |
|
|
|
|